Electronic CTD Guidance Forces Applicants To Be More Scientific, CDER Says
This article was originally published in The Pink Sheet Daily
CDER’s guidance for electronic common technical documents eliminates the need for paper submissions for virtually every type of drug application. The eCTD forces companies to be more scientific and analyze what they are submitting to FDA, CDER’s Wilson says.
You may also be interested in...
The final guidance provides three resources companies can access for assistance with SPL. FDA expects label changes for approved drugs will be submitted electronically using SPL by fall; the agency has not yet established a timeframe for unapproved drug labels.
Datasets are needed to support analysis, programs or scripts used in an electronic regulatory submission, CDER Division of Biometrics II Deputy Director Wilson tells DIA symposium on clinical data management. Agency may eventually require analysis datasets to supplement standardized electronic clinical data submissions.
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.